Email this article 
Difficulties and Prospects of Primary Liver Cancer Treatment
Abstract
Full Text:
Download PDFReferences
Chen W, Zheng R, Baade PD, et al., 2016, Cancer Statistics in China, 2015. CA Cancer J Clin, 66(2):115–32.
Department of Medical Administration, National Health and Health Commission of the People’s Republic of China, 2020, Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 edition). Zhonghua Gan Zang Bing Za Zhi, 28(2):112–28. DOI: 10.21147/j.issn.1000- 9604.2019.01.01.
Heimbach JK, Kulik LM, Finn RS, et al., 2018, AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology, 67(1):358–80. DOI: 10.1002/hep.29086.
Cammà C, Schepis F, Orlando A, et al., 2002, Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials. Radiology, 224(1):47–54. DOI: 10.1148/radiol.2241011262.
Sheta E, El-Kalla F, El-Gharib M, et al., 2016, Comparison of Single-session Transarterial Chemoembolization Combined with Microwave Ablation or Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Randomized-Controlled Study. Eur J Gastroenterol Hepatol, 28(10):1198–203. DOI: 10.1097/meg.0000000000000688.
Yang G, Xiong Y, Sun J, et al., 2020, The Efficacy of Microwave Ablation Versus Liver Resection in the Treatment of Hepatocellular Carcinoma and Liver Metastases: A Systematic Review and Meta-analysis. Int J Surg, 2020:S1743–9191. DOI: 10.1016/j.ijsu.2020.03.006.
Ohri N, Dawson LA, Krishnan S, et al., 2016, Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst, 108(9):djw133. DOI: 10.1093/jnci/djw133.
Qin S, Bai Y, Lim HY, et al. 2013, Randomized, Multicenter, Open-label Study of Oxaliplatin Plus Fluorouracil/leucovorin Versus Doxorubicin as Palliative Chemotherapy in Patients with Advanced Hepatocellular Carcinoma from Asia. J Clin Oncol, 31(28):3501–8. DOI: 10.3410/f.718087041.793483842.
Llovet JM, Ricci S, Mazzaferro V, et al., 2008, Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med, 359:378–90.
El-Khoueiry AB, Sangro B, Yau T, et al., 2017, Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-label, Non-comparative, Phase 1/2 dose Escalation and Expansion Trial. Lancet. 389(10088):2492–502. DOI: 10.1016/s0140- 6736(17)31046-2.
DOI: http://dx.doi.org/10.18063/ghl.v2i1.245
Refbacks
- There are currently no refbacks.
Copyright (c) 2020 Jin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Recent Articles | About Journal | For Author | Fees | About Whioce
Copyright © Whioce Publishing Pte Ltd. All Rights Reserved.